(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $9.40
发出时间: 15 Feb 2024 @ 02:07
回报率: -25.11%
上一信号: Feb 15 - 00:58
上一信号:
回报率: 1.68 %
Live Chart Being Loaded With Signals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications...
Stats | |
---|---|
今日成交量 | 1.14M |
平均成交量 | 1.24M |
市值 | 923.50M |
EPS | $0 ( 2024-05-02 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.52 |
ATR14 | $0.0110 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Rahmer Peter | Sell | 1 345 | Common Stock |
2024-04-29 | Adams Brian | Sell | 1 623 | Common Stock |
2024-04-29 | Catinazzo Thomas | Sell | 1 695 | Common Stock |
2024-04-29 | Bergstrom Donald A | Sell | 2 686 | Common Stock |
2024-03-27 | Catinazzo Thomas | Sell | 348 | Common Stock |
INSIDER POWER |
---|
88.11 |
Last 99 transactions |
Buy: 4 152 455 | Sell: 364 261 |
音量 相关性
Relay Therapeutics, Inc. 相关性 - 货币/商品
Relay Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $25.55M |
毛利润: | $20.28M (79.37 %) |
EPS: | $-2.79 |
FY | 2023 |
营收: | $25.55M |
毛利润: | $20.28M (79.37 %) |
EPS: | $-2.79 |
FY | 2022 |
营收: | $1.38M |
毛利润: | $-2.75M (-199.06 %) |
EPS: | $-2.27 |
FY | 2021 |
营收: | $3.03M |
毛利润: | $3.03M (100.00 %) |
EPS: | $-3.93 |
Financial Reports:
No articles found.
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。